A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Influenza A

In brief

The purpose of this study is to evaluate the efficacy, safety, and tolerability of VIR-2482 compared to placebo in preventing influenza A illness in healthy adults 18 to \<65 years of age without pre-existing risk factors for serious complications from influenza infection.

Key facts

Study ID

NCT05567783

Run by

Vir Biotechnology, Inc.

People needed

2977

Starts

2022-10-30

Expected to finish

2023-08-31

Last updated by the study team

2024-09-19

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Participant must be 18 to < 65 years of age, at time of randomization
• Participants must be in good health, determined from medical history and no clinically significant findings from physical examination, 12-lead electrocardiogram (ECG), vital signs, and laboratory values

You may not qualify if…

• History or clinical evidence of conditions considered high risk for developing influenza-related complications
• History of confirmed influenza infection within 3 months prior to randomization.
• Febrile illness with or without respiratory symptoms
• History of malignancy within 5 years or participant is under evaluation for malignancy.
• Any condition or receipt of any medication contraindicating IM injection, as judged by the investigator.
• History of a severe allergic reaction with generalized urticaria, angioedema or anaphylaxis
• Participant has a clinically significant medical condition, physical exam finding, or abnormal laboratory result.
• Prior or planned receipt of any influenza vaccine for the upcoming season.
• Received any investigational agent within 90 days or within 5 half-lives of the investigational agent.

Where it is running

• Investigative Site — Mobile, Alabama, United States
• Investigative Site — Tempe, Arizona, United States
• Investigative Site — Long Beach, California, United States
• Investigative Site — Pomona, California, United States
• Investigative Site — San Diego, California, United States
• Investigative Site — Aurora, Colorado, United States
• Investigative Site — Longmont, Colorado, United States
• Investigative Site — Fort Myers, Florida, United States
• Investigative Site — Jupiter, Florida, United States
• Investigative Site — Miami, Florida, United States
• Investigative Site — Miami, Florida, United States
• Investigative Site — Pembroke Pines, Florida, United States
• Investigative Site — Winter Park, Florida, United States
• Investigative Site — Lilburn, Georgia, United States
• Investigative Site — Meridian, Idaho, United States
• Investigative Site — Chicago, Illinois, United States
• Investigative Site — South Bend, Indiana, United States
• Investigative Site — El Dorado, Kansas, United States
• Investigative Site — Lenexa, Kansas, United States
• Investigative Site — Wichita, Kansas, United States
• Investigative Site — Lexington, Kentucky, United States
• Investigative Site — Versailles, Kentucky, United States
• Investigative Site — Metairie, Louisiana, United States
• Investigative Site — New Orleans, Louisiana, United States
• Investigative Site — Anniston, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.